|
US6374762B1
(en)
*
|
1997-10-27 |
2002-04-23 |
Correct Craft, Inc. |
Water sport towing apparatus
|
|
ES2193875B2
(en)
*
|
2002-04-09 |
2005-03-01 |
Laboratorios Del Dr. Esteve, S.A. |
DERIVATIVES OF BENZOXAZINONA, ITS PREPARATION AND ITS APPLICATION AS MEDICATIONS.
|
|
US20040242572A1
(en)
*
|
2002-08-24 |
2004-12-02 |
Boehringer Ingelheim International Gmbh |
New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture
|
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
|
KR101120414B1
(en)
|
2003-04-24 |
2012-04-12 |
인사이트 코포레이션 |
Aza spiro alkane derivatives as inhibitors of metalloproteases
|
|
EP2305352A1
(en)
|
2004-04-02 |
2011-04-06 |
Merck Sharp & Dohme Corp. |
5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders
|
|
MX2007001540A
(en)
*
|
2004-08-10 |
2007-04-23 |
Incyte Corp |
Amido compounds and their use as pharmaceuticals.
|
|
US7786141B2
(en)
*
|
2004-08-19 |
2010-08-31 |
Vertex Pharmaceuticals Incorporated |
Dihydrospiroindene modulators of muscarinic receptors
|
|
EP1781288A2
(en)
*
|
2004-08-19 |
2007-05-09 |
Vertex Pharmaceuticals Incorporated |
Modulators of muscarinic receptors
|
|
CA2579204A1
(en)
*
|
2004-09-07 |
2006-03-16 |
Banyu Pharmaceutical Co., Ltd. |
Carbamoyl-substituted spiro derivative
|
|
AU2005309365B2
(en)
*
|
2004-11-29 |
2011-10-06 |
Vertex Pharmaceuticals Incorporated |
Modulators of muscarinic receptors
|
|
AU2006297443B2
(en)
|
2005-09-29 |
2010-08-12 |
Merck Sharp & Dohme Corp. |
Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
|
|
WO2007055418A1
(en)
*
|
2005-11-10 |
2007-05-18 |
Banyu Pharmaceutical Co., Ltd. |
Aza-substituted spiro derivative
|
|
UA94433C2
(en)
*
|
2005-11-10 |
2011-05-10 |
Баниу Фармасьютикал Ко., Лтд. |
Aza-substituted spiro derivative
|
|
US7858635B2
(en)
*
|
2005-12-22 |
2010-12-28 |
Vertex Pharmaceuticals Incorporated |
Spiro compounds as modulators of muscarinic receptors
|
|
JP2009527569A
(en)
|
2006-02-22 |
2009-07-30 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Modulator of muscarinic receptor
|
|
AU2007221214A1
(en)
|
2006-02-22 |
2007-09-07 |
Vertex Pharmaceuticals Incorporated |
Modulators of muscarinic receptors
|
|
US7910108B2
(en)
|
2006-06-05 |
2011-03-22 |
Incyte Corporation |
Sheddase inhibitors combined with CD30-binding immunotherapeutics for the treatment of CD30 positive diseases
|
|
WO2008005295A2
(en)
*
|
2006-06-29 |
2008-01-10 |
Vertex Pharmaceuticals Incorporated |
Modulators of muscarinic receptors
|
|
AU2007284548A1
(en)
*
|
2006-08-15 |
2008-02-21 |
Vertex Pharmaceuticals Incorporated |
Modulators of muscarinic receptors
|
|
AU2007284350A1
(en)
*
|
2006-08-18 |
2008-02-21 |
Vertex Pharmaceuticals Incorporated |
Modulators of muscarinic receptors
|
|
AU2007300627B2
(en)
|
2006-09-22 |
2012-02-16 |
Merck Sharp & Dohme Corp. |
Method of treatment using fatty acid synthesis inhibitors
|
|
JP5319518B2
(en)
|
2007-04-02 |
2013-10-16 |
Ｍｓｄ株式会社 |
Indoledione derivative
|
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
|
CA2688161C
(en)
|
2007-06-04 |
2020-10-20 |
Kunwar Shailubhai |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
|
MX2010003373A
(en)
*
|
2007-10-03 |
2010-04-30 |
Vertex Pharma |
Modulators of muscarinic receptors.
|
|
JP5451646B2
(en)
*
|
2008-02-27 |
2014-03-26 |
ヴァイティー ファーマシューティカルズ，インコーポレイテッド |
Inhibitors of 11β-hydroxysteroid dehydrogenase type 1
|
|
EP2328910B1
(en)
|
2008-06-04 |
2014-08-06 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
|
EP3241839B1
(en)
|
2008-07-16 |
2019-09-04 |
Bausch Health Ireland Limited |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
|
|
EP2348857B1
(en)
|
2008-10-22 |
2016-02-24 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
|
PE20110852A1
(en)
|
2008-10-30 |
2011-11-25 |
Merck Sharp & Dohme |
ISONICOTINAMIDE OREXIN RECEPTOR ANTAGONISTS
|
|
AU2009309037A1
(en)
|
2008-10-31 |
2010-05-06 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
|
WO2011069298A1
(en)
*
|
2009-12-11 |
2011-06-16 |
F. Hoffmann-La Roche Ag |
Novel cyclopropane indolinone derivatives
|
|
CN102656147A
(en)
*
|
2009-12-11 |
2012-09-05 |
霍夫曼-拉罗奇有限公司 |
Spiro indole-cyclopropane indolinones useful as AMPK modulators
|
|
JP2013520502A
(en)
|
2010-02-25 |
2013-06-06 |
メルク・シャープ・エンド・ドーム・コーポレイション |
Novel cyclic benzimidazole derivatives that are useful anti-diabetic drugs
|
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
|
WO2012088266A2
(en)
|
2010-12-22 |
2012-06-28 |
Incyte Corporation |
Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
|
|
JP5728099B2
(en)
|
2011-02-25 |
2015-06-03 |
メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． |
Novel cyclic azabenzimidazole derivatives useful as antidiabetic agents
|
|
AR088352A1
(en)
|
2011-10-19 |
2014-05-28 |
Merck Sharp & Dohme |
ANTAGONISTS OF THE RECEIVER OF 2-PIRIDILOXI-4-NITRILE OREXINE
|
|
EP2847181A1
(en)
|
2012-05-11 |
2015-03-18 |
AbbVie Inc. |
Pyridazine and pyridine derivatives as nampt inhibitors
|
|
NZ702747A
(en)
|
2012-06-13 |
2017-03-31 |
Incyte Holdings Corp |
Substituted tricyclic compounds as fgfr inhibitors
|
|
RU2015106909A
(en)
|
2012-08-02 |
2016-09-27 |
Мерк Шарп И Доум Корп. |
ANTI-DIABETIC TRICYCLIC COMPOUNDS
|
|
WO2014026125A1
(en)
|
2012-08-10 |
2014-02-13 |
Incyte Corporation |
Pyrazine derivatives as fgfr inhibitors
|
|
US9266892B2
(en)
|
2012-12-19 |
2016-02-23 |
Incyte Holdings Corporation |
Fused pyrazoles as FGFR inhibitors
|
|
WO2014130608A1
(en)
|
2013-02-22 |
2014-08-28 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
|
EP2970119B1
(en)
|
2013-03-14 |
2021-11-03 |
Merck Sharp & Dohme Corp. |
Novel indole derivatives useful as anti-diabetic agents
|
|
WO2014151206A1
(en)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase and their uses
|
|
HK1220611A1
(en)
|
2013-03-15 |
2017-05-12 |
Bausch Health Ireland Limited |
Compositions useful for the treatment of gastrointestinal disorders
|
|
LT2986610T
(en)
|
2013-04-19 |
2018-04-10 |
Incyte Holdings Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
CN113388007A
(en)
|
2013-06-05 |
2021-09-14 |
博士医疗爱尔兰有限公司 |
Ultra-pure agonists of guanylate cyclase C, methods of making and using the same
|
|
WO2015051496A1
(en)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
|
US10851105B2
(en)
|
2014-10-22 |
2020-12-01 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
|
US9580423B2
(en)
|
2015-02-20 |
2017-02-28 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
|
MA41551A
(en)
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
BICYCLIC HETEROCYCLES USED AS FGFR4 INHIBITORS
|
|
SG10201913036RA
(en)
|
2015-02-20 |
2020-02-27 |
Incyte Corp |
Bicyclic heterocycles as fgfr inhibitors
|
|
EP3551176A4
(en)
|
2016-12-06 |
2020-06-24 |
Merck Sharp & Dohme Corp. |
ANTIDIABETIC HETEROCYCLIC COMPOUNDS
|
|
WO2018118670A1
(en)
|
2016-12-20 |
2018-06-28 |
Merck Sharp & Dohme Corp. |
Antidiabetic spirochroman compounds
|
|
AR111960A1
(en)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR ITS PREPARATION
|
|
EP4309737A3
(en)
|
2018-05-04 |
2024-03-27 |
Incyte Corporation |
Solid forms of an fgfr inhibitor and processes for preparing the same
|
|
EP3788046B1
(en)
|
2018-05-04 |
2025-12-10 |
Incyte Corporation |
Salts of an fgfr inhibitor
|
|
EP3924058B1
(en)
|
2019-02-13 |
2026-01-07 |
Merck Sharp & Dohme LLC |
5-alkyl pyrrolidine orexin receptor agonists
|
|
WO2020167701A1
(en)
|
2019-02-13 |
2020-08-20 |
Merck Sharp & Dohme Corp. |
Pyrrolidine orexin receptor agonists
|
|
US11628162B2
(en)
|
2019-03-08 |
2023-04-18 |
Incyte Corporation |
Methods of treating cancer with an FGFR inhibitor
|
|
US11591329B2
(en)
|
2019-07-09 |
2023-02-28 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
EP4010314B1
(en)
|
2019-08-08 |
2024-02-28 |
Merck Sharp & Dohme LLC |
Heteroaryl pyrrolidine and piperidine orexin receptor agonists
|
|
WO2021067374A1
(en)
|
2019-10-01 |
2021-04-08 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
CR20220169A
(en)
|
2019-10-14 |
2022-10-27 |
Incyte Corp |
Bicyclic heterocycles as fgfr inhibitors
|
|
WO2021076728A1
(en)
|
2019-10-16 |
2021-04-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
CA3163875A1
(en)
|
2019-12-04 |
2021-06-10 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
KR20220131900A
(en)
|
2019-12-04 |
2022-09-29 |
인사이트 코포레이션 |
Derivatives of FGFR inhibitors
|
|
US12012409B2
(en)
|
2020-01-15 |
2024-06-18 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
WO2022040070A1
(en)
|
2020-08-18 |
2022-02-24 |
Merck Sharp & Dohme Corp. |
Bicycloheptane pyrrolidine orexin receptor agonists
|
|
CN112939864B
(en)
*
|
2021-01-29 |
2022-05-06 |
中国医科大学 |
Spiro[benzo[c]azepin-1,1'-cyclohexyl]-3-ones
|
|
US12065494B2
(en)
|
2021-04-12 |
2024-08-20 |
Incyte Corporation |
Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent
|
|
AR126102A1
(en)
|
2021-06-09 |
2023-09-13 |
Incyte Corp |
TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS
|
|
AR126101A1
(en)
|
2021-06-09 |
2023-09-13 |
Incyte Corp |
TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS
|